Alternative carriers in dry powder inhaler formulations

Drug Discovery Today

Volumn 19, Issue 5, 2014, Pages 618-626

  Rahimpour, Yahya ^a   Kouhsoltani, Maryam ^b   Hamishehkar, Hamed ^c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CARRIER; ERYTHRITOL; EXCIPIENT; LACTOSE; MANNITOL; SORBITOL; TREHALOSE;

AEROSOL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRY POWDER INHALER; PARTICLE SIZE; REVIEW; SURFACE PROPERTY; ANIMAL; DRUG EFFECTS; HUMAN; LUNG; MEDICINAL CHEMISTRY; PHYSIOLOGY; PROCEDURES;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; HUMANS; LUNG; MANNITOL; SORBITOL;

EID: 84901505530     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.11.013     Document Type: Review

References (113)

1. W. Kaialy et al. The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers Colloids Surf. B: Biointerfaces 89 2011 29 39
2. W. Kaialy, and A. Nokhodchi Antisolvent crystallisation is a potential technique to prepare engineered lactose with promising aerosolisation properties: effect of saturation degree Int. J. Pharm. 437 2012 57 69
3. W. Kaialy et al. Characterisation and deposition studies of recrystallised lactose from binary mixtures of ethanol/butanol for improved drug delivery from dry powder inhalers AAPS J. 13 2011 30 43
4. W. Kaialy et al. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate Int. J. Pharm. 423 2011 184 194
5. W. Kaialy et al. Improved aerosolization performance of salbutamol sulfate formulated with lactose crystallized from binary mixtures of ethanol - acetone J. Pharm. Sci. 100 2011 2665 2684
6. J.S. Patton, and R.M. Platz Pulmonary delivery of peptides and proteins for systemic action Adv. Drug Deliv. Rev. 8 1992 179 228
7. Y. Rahimpour, and H. Hamishehkar Lactose engineering for better performance in dry powder inhalers Adv. Pharm. Bull. 2 2012 183 187
8. European Commission-Health & Consumer Protection Directorate Provisional statement on the safety of calf-derived rennet for the manufacture of pharmaceutical grade lactose 2002 Available at: http://ec.europa.eu/food/fs/ sc/ssc/out255-en.pdf
9. A. Glasnapp Alternatives for the lactose-intolerant patient Int. J. Pharm. Compd. 2 1998 412 413
10. H. Hamishehkar et al. Effect of carrier morphology and surface characteristics on the development of respirable PLGA microcapsules for sustained-release pulmonary delivery of insulin Int. J. Pharm. 389 2010 74 85
11. H. Hamishehkar et al. Pharmacokinetics and pharmacodynamics of controlled release insulin loaded PLGA microcapsules using dry powder inhaler in diabetic rats Biopharm. Drug. Dispos. 31 2010 189 201
12. H. Todo et al. Effect of additives on insulin absorption from intratracheally administered dry powders in rats Int. J. Pharm. 220 2001 101 110
13. J.F. Carpenter et al. Rational design of stable lyophilized protein formulations: some practical advice Pharm. Res. 14 1997 969 975
14. D. Prime et al. Review of dry powder inhalers Adv. Drug Deliv. Rev. 26 1997 51 58
15. H. Hamishehkar et al. Influence of carrier particle size, carrier ratio and addition of fine ternary particles on the dry powder inhalation performance of insulin-loaded PLGA microcapsules Powder Technol. 201 2010 289 295
16. K. Iida et al. Effect of surface covering of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate Chem. Pharm. Bull. 51 2003 1455 1457
17. H. Schiavone et al. Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers Int. J. Pharm. 281 2004 55 66
18. T. Sebti, and K. Amighi Preparation and in vitro evaluation of lipidic carriers and fillers for inhalation Eur. J. Pharm. Biopharm. 63 2006 51 58
19. G. Pilcer et al. Lactose characteristics and the generation of the aerosol Adv. Drug Deliv. Rev. 64 2012 233 256
20. D. Traini, and P.M. Young Formulation of inhalation medicines P. Colombo, In Inhalation Drug Delivery: Techniques and Products 2013 John Wiley & Sons 31 45
21. M.J. Telko, and A.J. Hickey Dry powder inhaler formulation Resp. Care 50 2005 1209 1227
22. U.H. Cegla Pressure and inspiratory flow characteristics of dry powder inhalers Respir. Med. 98 2004 S22 S28
23. C.A. Dunbar et al. A comparison of dry powder inhaler dose delivery characteristics using a power criterion PDA. J. Pharm. Sci. Technol. 54 2000 478 484
24. R.J. Malcolmson, and J.K. Embleton Dry powder formulations for pulmonary delivery Pharm. Sci. Technol. Today 1 1998 394 398
25. X.M. Zeng et al. The influence of carrier morphology on drug delivery by dry powder inhalers Int. J. Pharm. 200 2000 93 106
26. X.M. Zeng et al. The inuence of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols Int. J. Pharm. 197 2000 41 52
27. M.-N. Momin et al. Investigation into alternative sugars as potential carriers for dry powder formulation of budesonide BioImpacts 1 2011 105 111
28. H. Hamishehkar et al. The role of carrier in dry powder inhaler A.D. Sezer, Recent Advances in Novel Drug Carrier Systems 2012 InTech 39 66
29. H. Steckel, and N. Bolzen Alternative sugars as potential carriers for dry powder inhalations Int. J. Pharm. 270 2004 297 306
30. G. Saint-Lorant et al. Influence of carrier on the performance of dry powder inhalers Int. J. Pharm. 334 2007 85 91
31. W. Kaialy et al. The enhanced aerosol performance of salbutamol from dry powders containing engineered mannitol as excipient Int. J. Pharm. 392 2010 178 188
32. H.M. Mansour et al. Dry powder aerosols generated by standardized entrainment tubes from alternative sugar blends: 3. Trehalose dihydrate and d-mannitol carriers J. Pharm. Sci. 99 2010 3430 3441
33. P. Tang et al. Characterisation and aerosolisation of mannitol particles produced via confined liquid impinging jets Int. J. Pharm. 367 2009 51 57
34. H. Adi et al. Co-spray-dried mannitol-ciprooxacin dry powder inhaler formulation for cystic brosis and chronic obstructive pulmonary disease Eur. J. Pharm. Sci. 40 2010 239 247
35. E.M. Littringer et al. Spray dried mannitol carrier particles with tailored surface properties - the influence of carrier surface roughness and shape Eur. J. Pharm. Biopharm. 82 2012 194 204
36. W. Kaialy et al. Effect of carrier particle shape on dry powder inhaler performance Int. J. Pharm. 421 2011 12 23
37. P. Harjunen et al. Effects of carriers and storage of formulation on the lung deposition of a hydrophobic and hydrophilic drug from a DPI Int. J. Pharm. 263 2003 151 163
38. W. Kaialy et al. Engineered mannitol as an alternative carrier to enhance deep lung penetration of salbutamol sulphate from dry powder inhaler Colloids Surf. B: Biointerfaces 79 2010 345 356
39. W. Kaialy, and A. Nokhodchi Freeze-dried mannitol for superior pulmonary drug delivery via dry powder inhaler Pharm. Res. 30 2013 458 477
40. W. Kaialy, and A. Nokhodchi Treating mannitol in a saturated solution of mannitol: a novel approach to modify mannitol crystals for improved drug delivery to the lungs Int. J. Pharm. 448 2013 58 70
41. W. Kaialy et al. The effect of engineered mannitol-lactose mixture on dry powder inhaler performance Pharm. Res. 29 2012 2139 2156
42. P.M. Young et al. Composite carriers improve the aerosolisation efficiency of drugs for respiratory delivery J. Aerosol. Sci. 39 2008 82 93
43. A. Pomázi et al. Effect of polymers for aerolisation properties of mannitol based microcomposites containing meloxicam Eur. Polym. J. 49 2013 2518 2527
44. C. Bosquillon et al. Aerosolization properties, surface composition and physical state of spray-dried protein powders J. Control. Release 99 2004 357 367
45. S. Schüle et al. Stabilization of IgG1 in spray-dried powders for inhalation Eur. J. Pharm. Biopharm. 69 2008 793
46. S. Schüle et al. Conformational analysis of protein secondary structure during spray-drying of antibody/mannitol formulations Eur. J. Pharm. Biopharm. 65 2007 1 9
47. W.L. Hulse et al. Do co-spray dried excipients offer better lysozyme stabilisation than single excipients? Eur. J. Pharm. Sci. 33 2008 294 305
48. H.X. Ong et al. The effects of mannitol on the transport of ciprofloxacin across respiratory epithelia Mol. Pharmaceut. 10 2013 2915 2924
49. D. Cline, and R. Dalby Predicting the quality of powders for inhalation from surface energy and area Pharm. Res. 19 2002 1274 1277
50. X. Li, and H.M. Mansour Physicochemical characterization and water vapor sorption of organic solution advanced spray-dried inhalable trehalose microparticles and nanoparticles for targeted dry powder pulmonary inhalation delivery AAPS PharmSciTech 12 2011 1420 1430
51. T. Sou et al. The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules Eur. J. Pharm. Biopharm. 83 2013 234 243
52. J.A.J. Lopes et al. Erythritol: crystal growth from the melt Int. J. Pharm. 388 2010 129 135
53. S. Cohen et al. Water sorption, binding and solubility of polyols J. Chem. Soc., Faraday Trans. 89 1993 3271 3275
54. I.C. Munro et al. Erythritol: an interpretive summary of biochemical, metabolic, toxicological and clinical data Food Chem. Toxicol. 36 1998 1139 1174
55. K. Endo et al. Erythritol-based dry powder of glucagon for pulmonary administration Int. J. Pharm. 290 2005 63 71
56. Y. Gonnissen et al. Development of directly compressible powders via co-spray drying Eur. J. Pharm. Biopharm. 67 2007 220 226
57. D. Traini et al. Comparative study of erythritol and lactose monohydrate as carriers for inhalation: atomic force microscopy and in vitro correlation Eur. J. Pharm. Sci. 27 2006 243 251
58. S. Li et al. Effects of reducing sugars on the chemical stability of human relaxin in the lyophilized state J. Pharm. Sci. 85 1996 873 877
59. D.C. Dubost et al. Characterization of a solid state reaction product from a lyophilized formulation of a cyclic heptapeptide: a novel example of an excipient-induced oxidation Pharm. Res. 13 1996 1811 1814
60. S.A. Cryan Carrier-based strategies for targeting protein and peptide drugs to the lungs AAPS J. 7 2005 20 41
61. R. Platz et al. Pharmaceutical aerosol formulation of solid polypeptide microparticles and method for the preparation thereof World Patent 9116038 1991
62. R. Platz et al. Process for preparing micronized polypeptide drugs US Patent 5354562 1994
63. S.K. Tee et al. The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate Int. J. Pharm. 208 2000 111 123
64. M.S. Hassan, and R. Lau Feasibility study of pollen-shape drug carriers in dry powder inhalation J. Pharm. Sci. 99 2010 1309 1321
65. G. Pilcer, and K. Amighi Formulation strategy and use of excipients in pulmonary drug delivery Int. J. Pharm. 392 2010 1 19
66. O.N. Ógáin et al. Particle engineering of materials for oral inhalation by dry powder inhalers. I. Particles of sugar excipients (trehalose and raffinose) for protein delivery Int. J. Pharm. 405 2011 23 35
67. X.M. Zeng et al. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers Int. J. Pharm. 333 2007 45 55
68. P.M. Young et al. Influence of humidity on the electrostatic charge and aerosol performance of dry powder inhaler carrier based systems Pharm. Res. 24 2007 963 970
69. J.C. Hooton et al. Predicting the behavior of novel sugar carriers for dry powder inhaler formulations via the use of a cohesive-adhesive force balance approach J. Pharm. Sci. 95 2006 1288 1297
70. D. Suraj et al. Pulmonary drug delivery using large, porous-hollow inhaled particles Int. J. Nat. Product Sci. 1 2012 35
71. D.A. Edwards et al. Large porous particles for pulmonary drug delivery Science 276 1997 1868 1871
72. K. Koushik, and U.B. Kompella Preparation of large porous deslorelin-PLGA microparticles with reduced residual solvent and cellular uptake using a supercritical carbon dioxide process Pharm. Res. 21 2004 524 535
73. R. Vanbever et al. Formulation and physical characterization of large porous particles for inhalation Pharm. Res. 16 1999 1735 1742
74. N.R. Labiris, and M.B. Dolovich Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications Br. J. Clin. Pharmacol. 56 2003 600 612
75. C.J. Musante et al. Factors affecting the deposition of inhaled porous drug particles J. Pharm. Sci. 91 2002 1590 1600
76. D.S. Dhanda et al. Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose J. Control. Release 168 2013 239 250
77. V. Gupta et al. Inhaled PLGA particles of prostaglandin E1 ameliorate symptoms and progression of pulmonary hypertension at a reduced dosing frequency Mol. Pharm. 10 2013 1655 1667
78. B. Patel et al. PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin J. Control. Release 162 2012 310 320
79. F. Ungaro et al. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs J. Control. Release 135 2009 25 34
80. Y. Yang et al. Development of highly porous large PLGA microparticles for pulmonary drug delivery Biomaterials 30 2009 1947 1953
81. A. Rawat et al. Inhalable large porous microspheres of low molecular weight hepar in vitro in vivo evaluation J. Control. Release 128 2008 224 232
82. A. Ben-Jebria et al. Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs Pharm. Res. 16 1999 555 561
83. D.-D. Pham et al. Formulation of pyrazinamide-loaded large porous particles for the pulmonary route: avoiding crystal growth using excipients Int. J. Pharm. 454 2013 668 677
84. L. Garcia-Contreras et al. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model Antimicrob. Agents Chemother. 51 2007 2830 2836
85. H. Steckel, and H.G. Brandes A novel spray-drying technique to produce low density particles for pulmonary delivery Int. J. Pharm. 278 2004 187 195
86. N. Tsapis et al. Direct lung delivery of para-aminosalicylic acid by aerosol particles Tuberculosis 83 2003 379 385
87. A.B. Watts, and R.O. Williams 3rd Nanoparticles for pulmonary delivery H.D.C. Smyth, A.J. Hickey, Controlled Pulmonary Drug Delivery 2011 Springer New York 335 366
88. H. Stass et al. Pharmacokinetics of ciprofloxacin PulmoSphere® inhalational powder J. Cyst. Fibros. 7 2008 S26
89. D.E. Geller et al. Novel tobramycin inhalation powder in cystic brosis subjects: pharmacokinetics and safety Pediatr. Pulm. 42 2007 307 313
90. M.T. Newhouse et al. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers Chest 124 2003 360 366
91. M.W. Konstan et al. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial Pediatr. Pulmonol. 46 2011 230 238
92. M.W. Konstan et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial J. Cyst. Fibros. 10 2011 54 61
93. L. Dellamary et al. Rational design of solid aerosols for immunoglobulin delivery by modulation of aerodynamic and release characteristics J. Control. Release 95 2004 489 500
94. H. Stass et al. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study Clin. Ther. 35 2013 1571 1581
95. A.I. Bot et al. Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract Pharm. Res. 17 2000 275 283
96. D.E. Geller et al. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology J. Aerosol. Med. Pulm. Drug Deliv. 24 2011 175 182
97. F. Ungaro et al. Engineering gas-foamed large porous particles for efcient local delivery of macromolecules to the lung Eur. J. Pharm. Sci. 41 2010 60 70
98. S.M. Setter et al. Inhaled dry powder insulin for the treatment of diabetes mellitus Clin. Ther. 29 2007 795 813
99. H. Lian et al. A self-complementary, self-assembling microsphere system: application for intravenous delivery of the antiepileptic and neuroprotectant compound felbamate J. Pharm. Sci. 89 2000 867 875
100. K. Mohnike et al. Continuous sc infusion with glucagon and intermittent sc treatment with octreotide in persistent hyperinsulinaemic hypoglycaemia of infancy (PHHI) Exp. Clin. Endocrinol. Diabetes 108 2000 S127
101. A. Pfützner et al. Technosphere™/Insulin-a new approach for effective delivery of human insulin via the pulmonary route Diabetes Technol. Ther. 4 2002 589 594
102. A. Leone-Bay, and M. Grant Technosphere® technology: a platform for inhaled protein therapeutics ONDrugDelivery 2006 8 11
103. O.J. Phung Technosphere insulin: an inhaled mealtime insulin for the treatment of type 1 and type 2 diabetes mellitus Formulary 46 2011 14 17
104. J. Carroll MannKind posts positive PhIII diabetes responses for inhaled insulin 2013 Available at: http://www.fiercebiotech.com/story/mannkind-soars- after-inhaled-afrezza-delivers-positive-phiii-results/2013-08-14
105. P. Baldrick Pharmaceutical excipient development: the need for preclinical guidance Regul. Toxicol. Pharm. 32 2000 210 218
106. N. Islam et al. Effect of carrier size on the dispersion of salmeterol xinafoate from interactive mixtures J. Pharm. Sci. 93 2004 1030 1038
107. V.V. Sethuraman, and A.J. Hickey Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug AAPS PharmSciTech 3 2002 7 16
108. X. Kou et al. Physico-chemical aspects of lactose for inhalation Am. J. Drug Deliv. 64 2012 220 232
109. H.D. Smyth, and A.J. Hickey Carriers in drug powder delivery: implications for inhalation system design Am. J. Drug Deliv. 3 2005 117 132
110. ® and its absorption in healthy volunteers J. Control. Release 97 2004 19 29
111. FDA Guidance for Industry: Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products 1998 FDA, CDER Available at: http://www.fda.gov/ cder/guidance/index.htmx
112. M. Hindle, and P.R. Byron Dose emissions from marketed dry powder inhalers Int. J. Pharm. 116 1995 169 177
113. A. De Boer et al. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers. Part 2: effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalers Int. J. Pharm. 138 1996 45 56